Rohto Advanced Research Hong Kong Limited (RARHK) has been established in January 2019 by Rohto Pharmaceutical Co., Ltd (ROHTO) in Japan. The core businesses of ROHTO are cosmetics, pharmaceutical products and functional foods. ROHTO has advantages in terms of basic research, for developing cell culture techniques and manufacturing, utilizing aseptic automated manufacturing system for our products such as eye drops and cosmetics.
Regenerative medicine is one of the focusing areas in ROHTO. A Phase 1/2 study of allogenic adipose-derived mesenchymal stromal cells against liver cirrhosis is under way since 2017 in Japan.
In accordance with the strategic planning and development of regenerative medicine and its related businesses, RARHK will take over the advantages and cutting-edge technologies of ROHTO. RARHK will conduct basic research on mesenchymal stromal cells and other possible candidate(s) for the upcoming new era of cell therapies.